The TERAV consortium teams are developing advanced strategies in cellular immunotherapy and gene therapy targeting central nervous system (CNS) diseases and cancer.
Program II focuses on the use of anti-CD19 CAR-T cells as an immunotherapy for glioblastoma multiforme (GBM), investigating their tumor infiltration dynamics, immune activation, and alternative delivery routes such as intrathecal and diploic administration.
Program III explores the neurotrophic and anti-inflammatory potential of diploic bone marrow-derived mesenchymal stem cells (DMSCs) compared to vertebral-derived MSCs (VMSCs) in ALS models, through in vivo grafts and in vitro cellular interactions.
Program IV centers on technological innovations including human blood-brain barrier (BBB) models, 2D/3D platforms for neurotoxicity screening, and optimized delivery systems using genetically or immunologically modified cells, nanoparticles, and adult stem cells.
The UPV team (Programs I and IV) is developing novel non-viral gene therapy products (gtATMPs) using lipid nanoparticles (LNPs) for safe and efficient in vivo and ex vivo delivery of genetic material. These LNPs are engineered for enhanced specificity, stability, and biodistribution, and tested in preclinical models of monogenic, neurological, and oncological diseases. The team also explores mRNA-loaded LNPs to induce immunogenic viral or xenogeneic antigens in tumor cells.
Together, both teams aim to integrate cell therapy, non-viral delivery vectors, and complex experimental models to produce innovative therapeutic tools for precision medicine.
